ACI’s 2nd Annual Summit on GLP-1 Law & Policy will take place June 4, 2026, in New York, bringing together industry leaders to examine the evolving legal, regulatory, and commercial challenges—ranging from FDA oversight and IP disputes to litigation and market strategy—shaping the rapidly growing GLP-1 drug market. Shareholder Evan Holden will present on a panel titled “Mass Torts, Pharmacovigilance, and Litigation Readiness,” which focuses on proactively managing safety monitoring and adverse events while preparing for potential mass torts, multidistrict litigation, and class action risks as demand grows and long-term impacts remain uncertain.